Maintien des traitements anti-TNF dans le rhumatisme psoriasique : étude rétrospective monocentrique

[1]  I. Olivieri,et al.  Advances in the management of psoriatic arthritis , 2014, Nature Reviews Rheumatology.

[2]  D. Gladman,et al.  Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study , 2014, Arthritis care & research.

[3]  D. Gladman,et al.  Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) , 2014, Annals of the rheumatic diseases.

[4]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[5]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial , 2013, The Lancet.

[6]  A. Loft,et al.  Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. , 2013, Arthritis and rheumatism.

[7]  D. M. van der Heijde,et al.  Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study , 2013, Annals of the rheumatic diseases.

[8]  D. M. van der Heijde,et al.  The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study , 2013, Annals of the rheumatic diseases.

[9]  X. Mariette,et al.  Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective , 2012, Annals of the rheumatic diseases.

[10]  D. Gladman,et al.  Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study , 2012, Annals of the rheumatic diseases.

[11]  P. Mease,et al.  Treatment of Psoriatic Arthritis with Tumor Necrosis Factor Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL) , 2012, The Journal of Rheumatology. Supplement.

[12]  M. Dougados,et al.  European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies , 2011, Annals of the rheumatic diseases.

[13]  M. Østergaard,et al.  Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. , 2011, Arthritis and rheumatism.

[14]  D. Symmons,et al.  Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register , 2009, Arthritis research & therapy.

[15]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[16]  D. Gladman,et al.  Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) , 2008, Annals of the rheumatic diseases.

[17]  P. Geborek,et al.  Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register , 2007 .

[18]  C. Roux,et al.  TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. , 2007, Joint, bone, spine : revue du rhumatisme.

[19]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[20]  J. Gómez-Reino,et al.  Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER , 2006, Arthritis research & therapy.

[21]  J. Gómez-Reino,et al.  Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period , 2006, Arthritis research & therapy.

[22]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[23]  D. Gladman,et al.  Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). , 2005, Arthritis and rheumatism.

[24]  A. Kavanaugh,et al.  Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial , 2005, Annals of the rheumatic diseases.

[25]  P. Mease,et al.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.

[26]  B. Cortet,et al.  Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: a twelve-year "real life" experience. , 2015, Joint, bone, spine : revue du rhumatisme.